2010 Guidelines for antiretroviral treatment of HIV from the International AIDS Society-USA panel: Reply

JAMA

Volumn 304, Issue 17, 2010, Pages 1897-1898

  Thompson, Melanie A ^a   Günthard, Huldrych F ^b   Schooley, Robert T ^c  

^a AIDS Research Consortium of Atlanta   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LETTER; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEROCONVERSION; DRUG ADMINISTRATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PROGNOSIS;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 78049381259     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1562     Document Type: Letter

References (4)

1. Lyles RH, Muñoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men: Multicenter AIDS Cohort Study. J Infect Dis. 2000;181(3):872-880. (Pubitemid 30194468)
2. Mellors JW, Muñoz AM, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946-954.
3. Cozzi Lepri A, Sabin CA, Phillips AN, Lee CA, Pezzotti P, Rezza G. The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count: the Italian Seroconversion Study. Epidemiol Infect. 1998;121(2):369-376. (Pubitemid 28493155)
4. Wolbers M, Babiker A, Sabin C, et al; CASCADE Collaboration Members. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy: the CASCADE collaboration: a collaboration of 23 cohort studies. PLoS Med. 2010;7(2):e1000239.